Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb 20;32(6):587-600.
doi: 10.1200/JCO.2013.48.7934. Epub 2014 Jan 13.

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

Antonio Palumbo  1 , S Vincent Rajkumar, Jesus F San Miguel, Alessandra Larocca, Ruben Niesvizky, Gareth Morgan, Ola Landgren, Roman Hajek, Hermann Einsele, Kenneth C Anderson, Meletios A Dimopoulos, Paul G Richardson, Michele Cavo, Andrew Spencer, A Keith Stewart, Kazuyuki Shimizu, Sagar Lonial, Pieter Sonneveld, Brian G M Durie, Philippe Moreau, Robert Z Orlowski
Affiliations
Review

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

Antonio Palumbo et al. J Clin Oncol. .

Abstract

Purpose: To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation.

Methods: A comprehensive review of the literature on diagnostic criteria is provided, and treatment options and management of adverse events are summarized.

Results: Patients with symptomatic disease and organ damage (ie, hypercalcemia, renal failure, anemia, or bone lesions) require immediate treatment. The International Staging System and chromosomal abnormalities identify high- and standard-risk patients. Proteasome inhibitors, immunomodulatory drugs, corticosteroids, and alkylating agents are the most active agents. The presence of concomitant diseases, frailty, or disability should be assessed and, if present, treated with reduced-dose approaches. Bone disease, renal damage, hematologic toxicities, infections, thromboembolism, and peripheral neuropathy are the most frequent disabling events requiring prompt and active supportive care.

Conclusion: These recommendations will help clinicians ensure the most appropriate care for patients with myeloma in everyday clinical practice.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Treatment algorithm for elderly patients with multiple myeloma (MM). MEL 100, melphalan 100 mg/m2; MEL 200, melphalan 200 mg/m2; MPR-R, melphalan-prednisone-lenalidomide followed by lenalidomide; MPT, melphalan-prednisone-thalidomide; Rd, lenalidomide plus low-dose dexamethasone; Vd, bortezomib-dexamethasone; VCD, bortezomib-cyclophosphamide-dexamethasone; VMP, bortezomib-melphalanprednisone; VMPT-VT, bortezomibmelphalan-prednisone-thalidomide followed by bortezomib-thalidomide; VRD, bortezomib-lenalidomide-dexamethasone.
See this image and copyright information in PMC

References

    1. Altekruse SF, Kosary CL, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. http://seer.cancer.gov/csr/1975_2007/
    1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860–1873. - PubMed
    1. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review. Leukemia. 2009;23:2210–2221. - PMC - PubMed
    1. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009;23:1716–1730. - PubMed
    1. Bird JM, Owen RG, D'Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol. 2011;154:32–75. - PubMed